Image Credit: kirillvasilevcom/123rf.com
A recent clinical trial conducted by researchers at Johns Hopkins University has yielded promising results regarding smoking cessation methods. The study, which involved 82 current smokers, aimed to compare the effectiveness of psilocybin, the active compound found in magic mushrooms, against traditional nicotine patches.
Participants were divided into two groups, both receiving 13 weeks of cognitive behavioral therapy aimed at quitting smoking. One group utilized nicotine patches, while the other group was administered a single high dose of psilocybin in a guided session. During the psilocybin experience, participants were in a controlled environment, equipped with eye shades and soft music, allowing for a self-directed experience under the supervision of facilitators.
At the six-month follow-up, results revealed that 17 individuals from the psilocybin group remained cigarette-free, compared to only four in the nicotine patch group. This significant difference indicates that those who received psilocybin had over six times the odds of quitting smoking successfully.
The study design did not include a placebo group, which is a common challenge in psychedelic research. However, the findings are noteworthy enough to warrant a larger trial, which has already been funded by the National Institutes of Health. This upcoming study aims to include a placebo arm and a more diverse participant demographic to validate the initial results.
Currently, there are seven medications approved for smoking cessation in the United States, but their effectiveness remains limited, with long-term quit rates between 20 and 30 percent. Psilocybin presents a novel approach to smoking cessation, as it primarily alters the brain’s communication patterns, potentially leading to a transformative shift in perspective for participants.
This research builds on earlier studies into psychedelic treatments for addiction, with early indications of success in treating alcohol dependence and opioid use disorder. As smoking remains the leading cause of preventable death in the U.S., the demand for innovative cessation methods has never been more critical. The larger NIH-funded trial promises to further explore the implications of these findings and may contribute to a new era of addiction treatment.
Check out the original article here: Source link
